Vistin Pharma ASALTS:0RAM 77 Net Current Asset Value is kr2.58 as of Mar. 2026, which is 100% below its 10-year median of 9.15. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.61 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 610 Drug Manufacturers companies, Vistin Pharma ASA ranks worse than 62.3% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Vistin Pharma ASA's net current asset value per share for the quarter that ended in Mar. 2026 was kr2.58.
The historical rank and industry rank for Vistin Pharma ASA's Net Current Asset Value or its related term are showing as below:
LTS:0RAM'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.22 Med: 9.15 Max: 33.64
Current: 7.9
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Vistin Pharma ASA was 33.64. The lowest was 1.22. And the median was 9.15.
LTS:0RAM's Price-to-Net-Current-Asset-Value is ranked worse than 62.3% of 610
companies
in the Drug Manufacturers industry
Industry Median: 5.745
vs LTS:0RAM: 7.90
Vistin Pharma ASA (LTS:0RAM) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Vistin Pharma ASA Net Current Asset Value Related Terms
Vistin Pharma ASA Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAM vs ZTS, UTHR, VTRS: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of kr2.58 mean?
Vistin Pharma ASA (LTS:0RAM) has a Net Current Asset Value of kr2.58 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Vistin Pharma ASA and its competitors. This is 72% below median its historical median of 9.15. Over the past decade, Vistin Pharma ASA's Net Current Asset Value has ranged from 1.22 to 33.64. According to the industry distribution chart, Vistin Pharma ASA ranks #380 out of 610 companies in the Drug Manufacturers industry, placing it in the top 62.3%.
Is Vistin Pharma ASA's Net Current Asset Value too high?
Vistin Pharma ASA's current Net Current Asset Value of kr2.58 is 72% below median its 10-year median of 9.15. Over the past 10 years, this metric has ranged from a low of 1.22 to a high of 33.64. Based on the distribution chart, Vistin Pharma ASA ranks #380 out of 610 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Net Current Asset Value compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #380 out of 610 companies for Net Current Asset Value. This places Vistin Pharma ASA in the lower half of its industry. The industry median Net Current Asset Value is 5.75. Historically, Vistin Pharma ASA's own Net Current Asset Value has ranged from 1.22 to 33.64 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.75, based on 610 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Net Current Asset Value is kr2.58, which is 72% below median its own 10-year median of 9.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.61, compared to a current price of kr20.70 — trading 19.2% below its estimated fair value. The current Net Current Asset Value is kr2.58, which is 72% below median its 10-year median of 9.15. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Net Current Asset Value is kr2.58 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.70 is trading 19.2% below its estimated GF Value™ of kr25.61.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Net Current Asset Value: kr2.58 (72% below median its 10-year median of 9.15)
GF Value™: kr25.61 vs. price of kr20.70 (19.2% below fair value)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score
Get the complete analysis for LTS:0RAM
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
